

# PROVINCIAL FUNDING SUMMARY

Dacomitinib (Vizimpro) for Non-Small Cell Lung Cancer (pCODR 10129)

pERC Recommendation: Recommends with conditions  
 For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: June 17, 2019

This information is current as of July 1, 2020.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Negotiations with Manufacturer Unsuccessful		
AB	Negotiations with Manufacturer Unsuccessful		
SK	Negotiations with Manufacturer Unsuccessful		
MB	Negotiations with Manufacturer Unsuccessful		
ON	Negotiations with Manufacturer Unsuccessful		
NS	Negotiations with Manufacturer Unsuccessful		
NB	Not funded		
NL	Negotiations with Manufacturer Unsuccessful		
PEI	Negotiations with Manufacturer Unsuccessful		